ZOSTAVAXÂ® does not protect everyone, so some people who get the vaccine may still get shingles. However, if you develop shingles despite being vaccinated, ZOSTAVAXÂ® can help reduce the intensity and duration of pain.
ZOSTAVAXÂ® is indicated for the prevention of herpes zoster (shingles) and for immunization of individuals 50 years of age or older. ZOSTAVAXÂ® cannot be used to treat existing shingles or the pain associated with existing shingles. If you get shingles even though you have been vaccinated, see your healthcare provider promptly.
ZOSTAVAXÂ® should not be used if you: are allergic to any of the components of the vaccine, including gelatin or neomycin; have a blood disorder or any type of cancer that weakens your immune system; have been told by your doctor that you have a weakened immune system as a result of a disease, medications, or other treatment; have active untreated tuberculosis; are pregnant.
Women of childbearing age should take the necessary precautions to avoid pregnancy for 3 months following vaccination. Like all vaccines, ZOSTAVAXÂ® can have side effects. In studies, the most common side effects were at the injection site and included redness, pain, swelling, hard lump, itching, warmth, and bruising. Headache and pain in the arm or leg were also reported. Additional side effects reported in general use with ZOSTAVAXÂ® include allergic reactions, which may be serious and may include difficulty in breathing or swallowing, and fever. If you have an allergic reaction, call your doctor right away. Talk to your doctor or pharmacist for a more complete list of side effects for ZOSTAVAXÂ®.
OMICS International Organizes 1000+ Global Events. Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Accesswhich contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The Conference serieswebsite will provide you list and details about the conference organize worldwide.
Scope & Importance Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies. Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017. Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines. A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers. Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.
: Conferences from OMICS International: :
Protein Engineering Conference October 26-28, 2015 Chicago, USA
Vaccines Middle East Conference September 28-30, 2015 Dubai, UAE
Vaccines Asia Pacific Conference November 10-12, 2016 Melbourne, Australia
Vaccines 2015 November 30-December 02, 2015 San Francisco, USA
Euro Vaccines Conference June 16-18, 2016 Rome, Italy
Hepatities Vaccines Conference June 16-18, 2016 Rome, Italy
Hiv Vaccines Conference Oct 3-5, 2016 Miami, USA
Vaccines USA Conference November 30-December 02, 2015 San Francisco, USA
Proteomics Conference September 01-03, 2015 Valencia, Spain
World Proteomics Conference March 29-30, 2016 Atlanta, USA
Conferences out of OMICS:
2015 IMMUNIZATION SUMMIT! NAMPA, IDAHO MONDAY, SEPTEMBER 21, 2015
14th Annual Measles and Rubella Initiative Meeting: Focusing on the Human and Financial Costs of Measles Washington, USA September 15-16, 2015
19th Annual Conference on Vaccine Research April 18-20, 2016 Baltimore, MD
Clinical Vaccinology Course Bethesda, MD November 13, 2015
9th Vaccine & ISV Congress 18-20 October 2015 | Lotte Hotel, Seoul, South Korea
2016 North Dakota State Immunization Conference August 3-4, 2016, Bismarck, ND
Relevant societies and associations:
Immunization Action Coalition
The International Society for Vaccines
Center for Knowledge Societies
Applied Research on Cancer (ARC-NET)
The network of National Cancer Institutions of Latin America (RINC)
American Cancer Society
African Organization for Research & Training in Cancer (AORTIC)
GAVI, THE VACCINE ALLIANCE
Centre of Genomics and Policy (CGP)
Vaccine Delivery Innovation Initiative
Four Seasons Pharmacy
Dubai Health authority
Antivenom & vaccine Production centre
The centre for food security &public Health
National Institute of Agrobiological SciencesGenebank
This page will be updated regularly.
This page was last updated on December 8, 2023